

## Refine Search

---

### Search Results -

Term	Documents
3.PGPB.	1071
(L3 ).PGPB.	1071

---

**Database:**

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Search:**

L6

---

### Search History

---

**DATE:** Thursday, September 28, 2006    [Purge Queries](#)    [Printable Copy](#)    [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u>
side by side			result set
<i>DB=PGPB; PLUR=YES; OP=ADJ</i>			
<u>L6</u>	L3	1071	<u>L6</u>
<i>DB=USPT; PLUR=YES; OP=ADJ</i>			
<u>L5</u>	L3	387	<u>L5</u>
<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L4</u>	L3	79	<u>L4</u>
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L3</u>	tnf\$ same (antibod\$)same(chimeric or chimaeric or humaniz\$ or humanis\$)	1537	<u>L3</u>
<u>L2</u>	L1 and (Ca2 or a2 or infliximab or remicade) and tnf\$	112	<u>L2</u>
<u>L1</u>	le.in.	27174	<u>L1</u>

END OF SEARCH HISTORY

? s (tnf) (10n) (antibod? or hybridoma? or immunoglobulin?) (5n) (chimeric? or  
chimaeric? or humaniz? or humanis?)  
201026 TNF  
2128486 ANTIBOD?  
52600 HYBRIDOMA?  
787333 IMMUNOGLOBULIN?  
101066 CHIMERIC?  
3513 CHIMAERIC?  
14071 HUMANIZ?  
6000 HUMANIS?  
S12 739 (TNF) (10N) (ANTIBOD? OR HYBRIDOMA? OR  
IMMUNOGLOBULIN?) (5N) (CHIMERIC? OR CHIMAERIC? OR HUMANIZ?  
OR HUMANIS?)  
? s s12 and py<1992  
Processing  
739 S12  
32308520 PY<1992  
S13 15 S12 AND PY<1992  
? rd s13  
S14 7 RD S13 (unique items)  
? t s14/3/all

s (tnf) (10n) (antibod? or hybridoma? or immunoglobulin?) (5n) (chimeric? or chimaeric? or humaniz? or humanis?)  
201026 TNF  
2128486 ANTIBOD?  
52600 HYBRIDOMA?  
787333 IMMUNOGLOBULIN?  
101066 CHIMERIC?  
3513 CHIMAERIC?  
14071 HUMANIZ?  
6000 HUMANIS?  
S12 739 (TNF) (10N) (ANTIBOD? OR HYBRIDOMA? OR IMMUNOGLOBULIN?) (5N) (CHIMERIC? OR CHIMAERIC? OR HUMANIZ? OR HUMANIS?)

? s s12 and py<1992

Processing

739 S12  
32308520 PY<1992  
S13 15 S12 AND PY<1992  
? rd s13  
S14 7 RD S13 (unique items)  
? t s14/3/all

14/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008210343 BIOSIS NO.: 199293053234  
A TUMOR NECROSIS FACTOR TNF RECEPTOR-IGG HEAVY CHAIN CHIMERIC PROTEIN AS A BIVALENT ANTAGONIST OF TNF ACTIVITY  
AUTHOR: PEPPEL K (Reprint); CRAWFORD D; BEUTLER B  
AUTHOR ADDRESS: HOWARD HUGHES MED INST, UNIVERSITY TEXAS SOUTHWESTERN MED CENTER DALLAS, 5323 HARRY HINES BLVD, Y5-210, DALLAS, TX 75235, USA\*\*USA  
JOURNAL: Journal of Experimental Medicine 174 (6): p1483-1490 1991  
ISSN: 0022-1007  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

14/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007907277 BIOSIS NO.: 199242010168  
HUMANISED ANTIBODIES FOR ANTI-TNF THERAPY  
AUTHOR: EMTAGE S (Reprint); BODMER M  
AUTHOR ADDRESS: CELLTECH LTD, SLOUGH SL1 4EN, BERKS, UK\*\*UK  
JOURNAL: Cytokine 3 (5): p500 1991  
CONFERENCE/MEETING: THIRD INTERNATIONAL WORKSHOP ON CYTOKINES, STRESA, ITALY, NOVEMBER 10-14, 1991. CYTOKINE.  
ISSN: 1043-4666  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

14/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007890706 BIOSIS NO.: 199192136477  
CONSTRUCTION AND EXPRESSION OF ANTIBODY-TUMOR NECROSIS FACTOR FUSION PROTEINS  
AUTHOR: HOOGENBOOM H R (Reprint); VOLCKAERT G; RAUS J C M

AUTHOR ADDRESS: DR L WILLEMS INST, DEP WINF, LIMBURGS UNIV CENT, UNIV CAMPUS, B-3590 DIEPENBEEK, BELG\*\*BELGIUM  
JOURNAL: Molecular Immunology 28 (9): p1027-1038 1991  
ISSN: 0161-5890  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

14/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007809534 BIOSIS NO.: 199192055305  
TARGETING OF TUMOR NECROSIS FACTOR TO TUMOR CELLS SECRETION BY MYELOMA CELLS OF A GENETICALLY ENGINEERED ANTIBODY-TUMOR NECROSIS FACTOR HYBRID MOLECULE  
AUTHOR: HOOGENBOOM H R (Reprint); RAUS J C M; VOLCKAERT G  
AUTHOR ADDRESS: DR L WILLEMS-INSTITUUT, UNIVERSITAIRE CAMPUS, B-3610 DIEPENBEEK, BELG\*\*BELGIUM  
JOURNAL: Biochimica et Biophysica Acta 1096 (4): p345-354 1991  
ISSN: 0006-3002  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

14/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007540805 BIOSIS NO.: 199141053431  
NEUTRALIZING MOUSE-HUMAN CHIMERIC MONOCLONAL ANTIBODY MAB TO HUMAN TUMOR NECROSIS FACTOR TNF FOR THERAPY OF SEPTIC SHOCK  
AUTHOR: LE J (Reprint); SIEGEL S; KNIGHT D; SHEALY D; TRINH H; LEONE A; KINNEY C; ELY T; GHRAYEB J; VILCEK J; ET AL  
AUTHOR ADDRESS: NEW YORK UNIV MED CENT, NEW YORK, NY, USA\*\*USA  
JOURNAL: Abstracts of the General Meeting of the American Society for Microbiology 91 p62 1991  
CONFERENCE/MEETING: 91ST GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY 1991, DALLAS, TEXAS, USA, MAY 5-9, 1991. ABSTR GEN MEET AM SOC MICROBIOL.  
ISSN: 1060-2011  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

14/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007175201 BIOSIS NO.: 199089093092  
ANALYSIS OF THE STRUCTURE-FUNCTION RELATIONSHIP OF TUMOR NECROSIS FACTOR HUMAN-MOUSE CHIMERIC TNF PROTEINS GENERAL PROPERTIES AND EPITOPE ANALYSIS  
AUTHOR: TAVERNIER J (Reprint); MARMENOUT A; BAUDEN R; HAUQUIER G; VAN OSTADE X; FIERS W  
AUTHOR ADDRESS: LAB MOL BIOL, LEDEGANCKSTR 35, 9000 GHENT, BELG\*\*BELGIUM  
JOURNAL: Journal of Molecular Biology 211 (2): p493-502 1990  
ISSN: 0022-2836  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

14/3/7 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

07587911 PMID: 3131072  
Structure-function relationship of tumour necrosis factor and its mechanism of action.  
Fiers W; Brouckaert P; Goldberg A L; Kettelhut I; Suffys P; Tavernier J;  
Vanhaesebroeck B; Van Roy F  
Laboratory of Molecular Biology, State University of Ghent, Belgium.  
Ciba Foundation symposium (NETHERLANDS) 1987, 131 p109-23,  
ISSN 0300-5208--Print Journal Code: 0356636  
Publishing Model Print  
Document type: Journal Article; Review  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed  
? t s14/kwifc/all  
>>>"KWIFC" is not a valid format name in file(s): 5, 73, 155, 399  
? t s14/kwic/all  
>>>KWIC option is not available in file(s): 399

14/KWIC/1 (Item 1 from file: 5)  
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

1991

...ABSTRACT: activity compared with that of the bivalent inhibitor. Perhaps because of its high affinity for TNF, the chimeric protein is far more effective as a TNF inhibitor than are neutralizing monoclonal \*\*\*antibodies\*\*\* . This molecule may prove very useful as a reagent for the antagonism and assay of...

14/KWIC/2 (Item 2 from file: 5)  
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

HUMANISED ANTIBODIES FOR ANTI-TNF THERAPY

1991

14/KWIC/3 (Item 3 from file: 5)  
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

1991

...ABSTRACT: F(ab')2-like antibody-TNF fusion proteins. At the gene level, an antitransferrin receptor antibody heavy chain gene was linked to a synthetic gene coding for human \*\*\*TNF\*\*\* . The \*\*\*chimeric\*\*\* heavy chain-TNF genes were introduced into a light chain secreting transfecoma cell line, which was producing the...

14/KWIC/4 (Item 4 from file: 5)  
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

1991

...ABSTRACT: towards the human cancer cells was inhibited by an excess of the original antitransferrin receptor antibody, indicating that the antibody-TNF molecules are targeted to the transferrin receptor rich tumor cells. Since the \*\*\*antibody\*\*\* genes used are \*\*\*chimeric\*\*\* (i.e. composed of mouse variable and human constant

regions) and since DNA encoding human TNF was used, the hybrid protein is an example of a \*\*\*humanized\*\*\* immunotoxin-like molecule. These results illustrate the possibilities of antibody engineering technology to create and...

14/KWIC/5 (Item 5 from file: 5)  
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

NEUTRALIZING MOUSE-HUMAN CHIMERIC MONOCLONAL ANTIBODY MAB TO  
HUMAN TUMOR NECROSIS FACTOR TNF FOR THERAPY OF SEPTIC SHOCK  
1991

14/KWIC/6 (Item 6 from file: 5)  
DIALOG(R)File 5:(c) 2006 The Thomson Corporation. All rts. reserv.

1990

...ABSTRACT: E. coli as soluble proteins, a reduction of solubility was observed in some of the \*\*\*chimeric\*\*\* proteins. The specific activity was variable, but in some constructs comparable to human TNF, indicating that the structural conformation of these chimeric proteins resembled the human \*\*\*TNF\*\*\* structure. Neutralization analysis using two monoclonal antibodies directed against human TNF, indicated that the regions involved in the binding of these antibodies are distributed over multiple segments of the polypeptide. Further analysis by site-directed mutagenesis of...

14/KWIC/7 (Item 1 from file: 155)  
DIALOG(R)File 155:(c) format only 2006 Dialog. All rts. reserv.

... \*\*\*1987\*\*\*  
... interferon, whereas normal cells either are unaffected or respond mitogenically. A number of human-mouse \*\*\*chimeric\*\*\* \*\*\*TNF\*\*\* genes have been constructed and expressed. All show biological activity but none of the chimeric proteins is neutralized by monoclonal antibodies to \*\*\*TNF\*\*\*. \*\*\*TNF\*\*\* has potent antitumour activity in nude mice carrying human xenografts or in mice bearing syngeneic...?  
?